Penumbra Shares Are Trading Higher After the Company Announced It Completed the Enrollment in Its THUNDER Clinical Study for Patients With Acute Ischemic Stroke. Also, Truist Securities Maintained a Buy Rating on the Stock and Raised Its Price Target...

Benzinga · Oct 14 23:29

Penumbra Shares Are Trading Higher After the Company Announced It Completed the Enrollment in Its THUNDER Clinical Study for Patients With Acute Ischemic Stroke. Also, Truist Securities Maintained a Buy Rating on the Stock and Raised Its Price Target From $200 to $235.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.

Penumbra Shares Are Trading Higher After the Company Announced It Completed the Enrollment in Its THUNDER Clinical Study for Patients With Acute Ischemic Stroke. Also, Truist Securities Maintained a Buy Rating on the Stock and Raised Its Price Target...

Penumbra Shares Are Trading Higher After the Company Announced It Completed the Enrollment in Its THUNDER Clinical Study for Patients With Acute Ischemic Stroke. Also, Truist Securities Maintained a Buy Rating on the Stock and Raised Its Price Target From $200 to $235.

Risk Disclaimer